Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific's stock outlook is supported by impressive year-over-year growth in several key segments, including a 35% increase in Watchman sales and a remarkable 63% growth in its electrophysiology (EP) division, reflecting strong market demand and share gains. The company projects organic sales growth of 11-13% for Q4, alongside expected revenues of approximately $5.222 billion to $5.314 billion, showcasing robust overall growth momentum. Additionally, Boston Scientific's innovative product lines, such as the Nalu device anticipated to generate over $60 million in sales by 2025, further underscore the firm's potential for sustained financial performance and market expansion.

Bears say

Boston Scientific's outlook appears negative due to anticipated foreign exchange headwinds of approximately $0.04 per adjusted share, coupled with slight reductions in future revenue forecasts stemming from quarterly performance misses. The company faces significant challenges in its Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) portfolios, which operate in mature markets enduring persistent pricing pressure. Additionally, any setbacks in new product launches or difficulties in integrating acquisitions could further hinder Boston Scientific's growth potential, as reflected in missed performance expectations in various segments, including a notable shortfall in the Urology sector.

Boston Scientific (BSX) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 17 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.